33
Participants
Start Date
October 29, 2018
Primary Completion Date
December 28, 2021
Study Completion Date
December 28, 2021
PTC299
PTC299 will be administered per the treatment arm description
Columbia, New York
University of Rochester MC, Rochester
Duke Cancer Center, Durham
SCRI Tennessee Oncology, Nashville
Cleveland Clinic Foundation, Cleveland
Gabrail Cancer Center, Canton
Oncology Hematology Care, Inc., Cincinnati
Henry Ford Health System, Detroit
Texas Oncology, P.A., Fort Worth
MD Anderson Cancer Center, Houston
Texas Oncology, P.A. - San Antonio Medical Center, San Antonio
Texas Oncology, P.A., Austin
Rocky Mountain Cancer Center, Aurora
Swedish Cancer Institute, Seattle
Yale University, New Haven
Rutgers, Cancer Institute of NJ, New Brunswick
Rhode Island, Miriam Hospital, Providence
Lead Sponsor
PTC Therapeutics
INDUSTRY